Polaris Venture Management Co. V L.L.C. maintained its position in Bind Therapeutics Inc. (NASDAQ:BIND) during the second quarter, Holdings Channel reports. The institutional investor owned 2,018,253 shares of the company’s stock at the end of the second quarter. Bind Therapeutics makes up about 0.8% of Polaris Venture Management Co. V L.L.C.’s holdings, making the stock its 10th largest position. Polaris Venture Management Co. V L.L.C. owned 0.10% of Bind Therapeutics worth $789,000 as of its most recent filing with the SEC.

Separately, Jacobs Levy Equity Management Inc. purchased a new position in Bind Therapeutics during the first quarter valued at approximately $198,000.

Shares of Bind Therapeutics Inc. (NASDAQ:BIND) remained flat at $0.78 on Friday. Bind Therapeutics Inc. has a 12 month low of $0.35 and a 12 month high of $5.24. The company’s 50-day moving average price is $0.52 and its 200 day moving average price is $1.17.

Several research firms have commented on BIND. Zacks Investment Research downgraded Bind Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 11th. Stifel Nicolaus reiterated a “hold” rating on shares of Bind Therapeutics in a report on Wednesday, July 6th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $4.06.

Bind Therapeutics Company Profile

BIND Therapeutics, Inc is a biotechnology company. The Company is engaged in developing targeted therapeutics, primarily for the treatment of cancer. The Company’s product candidates are based on polymeric nanoparticles called ACCURINS, which are engineered to target specific cells and tissues in the body at sites of disease.

5 Day Chart for NASDAQ:BIND

Want to see what other hedge funds are holding BIND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bind Therapeutics Inc. (NASDAQ:BIND).

Receive News & Ratings for Bind Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bind Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.